Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies.
Sharon B WigalTim WigalMary HobartJessica J MaderaRoss A BakerEva KohegyiAnthony McKinneyTimothy E WilensPublished in: Neuropsychiatric disease and treatment (2020)
These results support the continued development of centanafadine-SR at doses up to 400 mg/d.
Keyphrases